Takeda Launches Narcolepsy Pill Orzeyful in US
The twice-daily prescription treatment targets the orexin loss behind narcolepsy type 1, a condition affecting about 120,000 Americans.
Updated on Nov. 12, 2026 in Sleep Disorders

Live Poll
Do you trust doctors to find and treat rare conditions like narcolepsy?
Takeda has made Orzeyful, its narcolepsy pill, available in the United States by prescription, after the Food and Drug Administration approved it in August for narcolepsy type 1. The Drug Enforcement Administration has classified Orzeyful as a Schedule IV controlled substance.
Why it matters
Orzeyful is designed to address the loss of orexin signaling that drives narcolepsy rather than only managing symptoms. Its availability gives patients who still have breakthrough symptoms on existing treatments a new option in the United States.
Clinical studies showed Orzeyful improved patients' ability to stay awake during the day and significantly reduced cataplexy compared with placebo. About 120,000 people in the US have narcolepsy type 1, and roughly half of those with the disease have not been diagnosed.
The players
Takeda
Takeda is a Japan-based pharmaceutical company developing Orzeyful for the treatment of narcolepsy type 1.
The details
Orzeyful is a twice-daily pill that targets the loss of orexin signaling caused by the death of brain cells that produce orexin. It will be dispensed through Cigna's Accredo Specialty Pharmacy, and the initial launch focuses on adults cycling through other treatments or taking multiple medications who still experience breakthrough symptoms.
Timeline
August 2026: The FDA approved Orzeyful for narcolepsy type 1.
November 12, 2026: Takeda announced Orzeyful is available in the US.
Health Landscape
Orzeyful represents a shift from symptom-focused narcolepsy treatment toward therapies that address the orexin deficiency underlying the disorder. Its prescription launch moves this mechanism-based approach into routine US clinical practice.
Patients with narcolepsy type 1 who still have breakthrough symptoms on current medications may discuss Orzeyful with their physicians. Because the drug is a Schedule IV controlled substance, it requires a prescription and is subject to federal controlled-substance handling rules.
The takeaway
Orzeyful offers a mechanism-based option for narcolepsy type 1, but since about half of people with the disease are undiagnosed, a conversation with a doctor about persistent daytime sleepiness or cataplexy is a practical first step.
Further reading
For more on treatment options, see Sleep Disorders coverage across the site.
Live Poll
Do you trust doctors to find and treat rare conditions like narcolepsy?






